A longitudinal case series of IM ketamine for patients with severe and enduring eating disorders and comorbid treatment‐resistant depression
Clinical Case Reports April 4, 2021 Terry Schwartz, Mary Ellen Trunko, David Feifel et al. 52 citations
Severe and enduring eating disorders carry the highest mortality rate of all psychiatric illnesses, especially when combined with treatment-resistant depression. Four patients with both conditions received repeated ketamine treatments over 12 or more months. Depression improved, but eating disorder symptoms changed only modestly.